Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma

被引:81
|
作者
Wojcicka, Anna [1 ,6 ]
Swierniak, Michal [1 ,4 ,5 ]
Kornasiewicz, Oskar [1 ]
Gierlikowski, Wojciech [1 ]
Maciag, Monika [1 ]
Kolanowska, Monika [1 ]
Kotlarek, Marta [1 ]
Gornicka, Barbara [2 ]
Koperski, Lukasz [2 ]
Niewinski, Grzegorz [3 ]
Krawczyk, Marek [1 ]
Jazdzewski, Krystian [1 ,6 ]
机构
[1] Med Univ Warsaw, Dept Gen Transplant & Liver Surg, PL-02091 Warsaw, Poland
[2] Med Univ Warsaw, Dept Pathol, PL-02091 Warsaw, Poland
[3] Med Univ Warsaw, Dept Anaesthesiol & Intens Therapy 2, PL-02091 Warsaw, Poland
[4] Maria Sklodowska Curie Mem Canc Ctr, Dept Nucl Med & Endocrine Oncol, PL-44101 Gliwice, Poland
[5] Inst Oncol, PL-44101 Gliwice, Poland
[6] Univ Warsaw, CENT, Ctr New Technol, Lab Human Canc Genet, PL-02089 Warsaw, Poland
关键词
Liver cancer; miRs; Isoforms; HCC; Deep sequencing; IN-DEPTH CHARACTERIZATION; HEPATITIS-B; EXPRESSION; TARGET; TRANSCRIPTOME; IDENTIFICATION; MICROARRAY; MUTATIONS; INSIGHTS; CANCER;
D O I
10.1016/j.biocel.2014.05.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatocellular carcinoma (HCC) represents the major histological subtype of liver cancer. Tumorigenic changes in hepatic tells potentially result from aberrant expression of microRNAs (miRNAs). Individual microRNA gene may give rise to miRNAs of different length, named isomiRNAs that proved to be functionally relevant. Since microRNA length heterogeneity in hepatic tissue has not been described before, we employed next-generation sequencing to comprehensively analyze microRNA transcriptome in HCC tumors (n = 24) and unaffected tissue adjacent to tumors (n = 24), including samples with (n = 15) and without cirrhosis (n = 9). We detected 374 microRNAs expressed in liver, including miR-122-5p that constituted over 39% of the hepatic miRnome. Among the liver expressed miRs, the levels of 64 significantly differed between tumor and control samples (FDR < 0.05, fold change >2). Top deregulated miRNAs included miR-1269a (T/N = 22.95), miR-3144-3p (T/N= 5.24), miR-183-5p (T/N= 4.63), miR-10b-5p (T/N= 3.87), miR-490-3p (TIN = 0.13), miR-199a-5p (T/N = 0.17), miR-199a-3p/miR-199b-3p (T/N= 0.19), miR-214-5p (TIN = 0.20) and miR-214-3p (T/N= 0.21). Almost all miRNA genes produced several mature molecules differing in length (isomiRNAs). The reference sequence was not the most prevalent in 38.6% and completely absent in 10.5% of isomiRNAs. Over 26.1% of miRNAs produced isoforms carrying >= 2 alternative seed regions, of which 35.5% constituted novel, previously unknown seeds. This fact sheds new light on the percentage of the human genome regulated by microRNAs and their variants. Among the most deregulated miRNAs, miR-199a-3p/miR-199b-3p (T/N fold change = 0.18, FDR= 0.005) was expressed in 9 isoforms with 3 different seeds, concertedly leading to upregulation of TGF-beta signaling pathway (OR= 1.99; p = 0.004). In conclusion, the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA-dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed Issue entitled: Rare Cancers. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:208 / 217
页数:10
相关论文
共 50 条
  • [31] Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis
    Palmieri, G
    Biondi, E
    Morabito, A
    Rea, A
    Gravina, A
    Bianco, AR
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 8 (04) : 827 - 832
  • [32] HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH LIVER CIRRHOSIS
    Resuli, B.
    Babameto, A.
    Basho, J.
    Shehu, K.
    Akshia, I.
    ANNALS OF ONCOLOGY, 2010, 21 : 113 - 113
  • [33] Management of liver cirrhosis in patients with hepatocellular carcinoma
    Ismail, Bahaa Eldeen Senousy
    Cabrera, Roniel
    CHINESE CLINICAL ONCOLOGY, 2013, 2 (04)
  • [34] Juvenile hepatocellular carcinoma with congestive liver cirrhosis
    Izumi, Y
    Hiramatsu, N
    Itose, I
    Inoue, T
    Sasagawa, A
    Egawa, S
    Nishida, T
    Kakiuchi, Y
    Toyama, T
    Nakanishi, F
    Ohkawa, K
    Mochizuki, K
    Kanto, T
    Tsujii, M
    Takehara, T
    Tsuji, S
    Kato, M
    Kasahara, A
    Hayashi, N
    JOURNAL OF GASTROENTEROLOGY, 2005, 40 (02) : 204 - 208
  • [35] Juvenile hepatocellular carcinoma with congestive liver cirrhosis
    Yuko Izumi
    Naoki Hiramatsu
    Ichiyo Itose
    Takahiro Inoue
    Akira Sasagawa
    Satoshi Egawa
    Tsutomu Nishida
    Yoshimi Kakiuchi
    Takashi Toyama
    Fumihiko Nakanishi
    Kazuyoshi Ohkawa
    Kiyoshi Mochizuki
    Tatsuya Kanto
    Masahiko Tsujii
    Tetsuo Takehara
    Shingo Tsuji
    Michio Kato
    Akinori Kasahara
    Norio Hayashi
    Journal of Gastroenterology, 2005, 40 : 204 - 208
  • [36] Liver resection for hepatocellular carcinoma in patients with cirrhosis
    Wu, CC
    Cheng, SB
    Ho, WM
    Chen, JT
    Liu, TJ
    Feng, FK
    BRITISH JOURNAL OF SURGERY, 2005, 92 (03) : 348 - 355
  • [37] Impact of Next-Generation Sequencing on Outcomes in Hepatocellular Carcinoma: How Precise Are We Really?
    Dominguez, Dana A.
    Wang, Xin Wei
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2020, 7 : 33 - 37
  • [38] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma
    Wong, Ching Ngar
    Fessas, Petros
    Dominy, Kathy
    Mauri, Francesco A.
    Kaneko, Takahiro
    Parcq, Persephone Du
    Khorashad, Jamshid
    Toniutto, Pierluigi
    Goldin, Robert D.
    Avellini, Claudio
    Pinato, David J.
    LIVER INTERNATIONAL, 2021, 41 (01) : 192 - 203
  • [39] Genetic heterogeneity in hepatocellular carcinoma and paired bone metastasis revealed by next-generation sequencing
    Jin, Ketao
    Lan, Huanrong
    Wang, Xuanwei
    Lv, Jieqing
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (10): : 10495 - 10504
  • [40] The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy
    Du, Jiajia
    Zhang, Erlei
    Huang, Zhiyong
    FRONTIERS IN IMMUNOLOGY, 2024, 15